European Commission Approves Keytruda-Padcev Bladder Cancer Treatment
The European Commission approved Merck’s Keytruda plus Padcev as perioperative treatment for adults with resectable muscle-invasive bladder cancer.
Story updates
10:45:44 AM UTC
SquawkNews
Merck said the European Commission approved Keytruda plus Padcev as perioperative therapy for adults with resectable muscle—invasive bladder cancer, regardless of cisplatin eligibility, based on Phase 3 KEYNOTE—B15 results.Material DetailsContext by AI AnalystThis is a late-stage regulatory win ext…
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the European Commission (EC) has approved KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Padcev® (enfortumab vedotin-ejfv), as neoadjuvant treatment and then continued after radical cy…